Expanding dermatology and women’s health product portfolio.
Development pipeline includes two high impact, rare skin disease product opportunities.
Accelerate CDMO platform globally
Realignment of cost base to improve profitability.
Net cash flow 9.8 for 1 H.
Positive operating cash flow of A$46.2m with strong cash conversion
Significant spend base reduction of A$20m (annualised) to further right size organisation and optimise global infrastructure and product development priorities'
Specialty Brands performance improved in the 2QFY20 with sales up 50% on 1QFY20
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.25 |
Change
-0.150(2.78%) |
Mkt cap ! $426.5M | |||
| Open | High | Low | Value | Volume |
| $5.35 | $5.41 | $5.19 | $1.239M | 231.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $5.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.36 | 1000 | 1 |
View Market Depth
| Last trade - 16.11pm 25/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |